
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.086 | -5.82655826558 | 1.476 | 1.54 | 1.325 | 1114423 | 1.4099121 | CS |
4 | -0.46 | -24.8648648649 | 1.85 | 2.025 | 1.325 | 1294710 | 1.62060077 | CS |
12 | -1.74 | -55.5910543131 | 3.13 | 3.13 | 1.325 | 1289793 | 2.11106511 | CS |
26 | -1.5 | -51.9031141869 | 2.89 | 3.305 | 1.325 | 1605035 | 2.58524709 | CS |
52 | -1.03 | -42.5619834711 | 2.42 | 3.45 | 1.325 | 1672502 | 2.52530575 | CS |
156 | -10.57 | -88.3779264214 | 11.96 | 12.8 | 1.325 | 1090337 | 3.45909389 | CS |
260 | -14.51 | -91.2578616352 | 15.9 | 24.47 | 1.325 | 987579 | 4.53800745 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.